Eli Lilly and Company (NYSE:LLY) Shares Down 2.5% – Should You Sell?

Eli Lilly and Company (NYSE:LLY) fell 2.5% during trading on Tuesday . The stock traded as low as $1,190.20 and last traded at $1,199.30. Approximately 3,700,387 shares changed hands during mid-day trading, an increase of 14% from the average daily volume of 3,241,918 shares. The stock had previously closed at $1,229.93.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and market commentary remain constructive on Lilly’s long-term outlook, citing leadership in GLP-1 therapies, an expanding pipeline, and a diversified growth strategy. Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?
• Positive Sentiment: GLP-1 demand is still viewed as a major industry growth driver, which supports Lilly’s obesity and diabetes franchise. Can pharma sustain its $2T trajectory?
• Positive Sentiment: TipRanks said AI could become a meaningful long-term growth tailwind for Eli Lilly by improving drug discovery and development productivity. AI Is the Ultimate Growth Tailwind for Eli Lilly (LLY). Here’s Why
• Positive Sentiment: Several analysts reiterated bullish views heading into earnings, pointing to multiple catalysts that could drive further upside. Several Analysts Pounds the Table on Eli Lilly Stock (LLY) Heading into Earnings
• Neutral Sentiment: Lilly also announced regional management changes in Korea and Romania, which appear operational rather than market-moving. Eli Lilly Korea names Komasu Seiya new representative
• Neutral Sentiment: Some coverage noted Lilly is still priced at a premium, and one analyst trimmed FY2027 EPS estimates slightly, suggesting valuation remains a watch item. Promising Pharmaceutical Stocks To Keep An Eye On – July 1st
• Negative Sentiment: Investors are also watching risks in China, including a U.S. lawmakers’ probe into Lilly’s clinical trial activities and a separate generic patent challenge to tirzepatide. Eli Lilly (LLY) Faces China Trial Security Probe From U.S. Lawmakers
• Negative Sentiment: China-related patent litigation over tirzepatide could create longer-term competitive and legal pressure on Lilly’s obesity franchise. China’s Hybio Challenges Eli Lilly Patents With First Generic Filing for Blockbuster Weight-Loss Drug Tirzepatide

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Morgan Stanley restated an “overweight” rating on shares of Eli Lilly and Company in a research report on Friday, June 5th. Leerink Partners boosted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Bank of America upped their price target on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 8th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,285.00 target price on shares of Eli Lilly and Company in a report on Friday, March 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,235.07.

Eli Lilly and Company Stock Up 1.4%

The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The firm has a 50-day simple moving average of $1,053.61 and a two-hundred day simple moving average of $1,025.60. The company has a market cap of $1.14 trillion, a PE ratio of 42.93, a P/E/G ratio of 1.49 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 35.74 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Institutional Trading of Eli Lilly and Company

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after purchasing an additional 1,006,885 shares during the last quarter. State Street Corp grew its holdings in Eli Lilly and Company by 1.8% in the 4th quarter. State Street Corp now owns 35,361,916 shares of the company’s stock valued at $38,002,744,000 after buying an additional 635,358 shares during the period. Capital Research Global Investors grew its holdings in Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after purchasing an additional 4,332,008 shares during the period. Morgan Stanley increased its position in Eli Lilly and Company by 2.7% during the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock worth $16,757,510,000 after purchasing an additional 407,166 shares during the last quarter. Finally, Capital World Investors raised its stake in Eli Lilly and Company by 0.4% during the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after purchasing an additional 61,851 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.